Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

Operating Margin · Q4 FY2025 · quarter ended Dec 2025

Operating margin at -77.0%

Operating margin was -77.0% in Q4 FY2025. Over 3 fiscal years it narrowed by 84.0 pp.

Context

  • Operating margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-77.0%+0.0 pp QoQ
Last fiscal yearDec 2025
-58.7%-67.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-67.5 pp——
3 years-84.0 pp——
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-58.7%
Year-over-year change
-67.5pp

Operating Margin vs competitors

How ZYBT compares with its peers on the latest reported figures

  • ZYBT's FY2025 operating margin of -58.7% is the 3rd highest of the 5 companies compared; the peer median is -290.7%.
  • Its year-over-year change of -67.5 pp is the 3rd highest of 5, against a peer median of -177.2 pp.
  • Over three fiscal years its change of -84.0 pp compares with a peer median of -426.0 pp.
ZYBT Competitors Peer median
Operating Margin for ZYBT and competitors
Company Period LTM level YoY 3-year change
PDEXPro-Dex, Inc.LTM Mar 202614.5% -3.8 pp+3.9 pp
APYXApyx Medical CorporationLTM Mar 2026-7.7% +24.6 pp+40.7 pp
ZYBTZhengye Biotechnology Holding LimitedFY2025-58.7% -67.5 pp-84.0 pp
SRZNSurrozen, Inc.LTM Mar 2026-573.8% -350.7 pp-855.9 pp
SERASera Prognostics, Inc.LTM Mar 2026-64235.1% -32245.5 pp-28032.3 pp
CRDLCardiol Therapeutics Inc.FY2025— ——
TILInstil Bio, Inc.FY2025— ——
ONCYOncolytics Biotech Inc.FY2025— ——
EXOZeXoZymes, Inc.FY2025— ——
Peer median (excluding ZYBT) -290.7%-177.2 pp-426.0 pp

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue214.07M260.27M211.65M186.36M116.36M
Cost of Revenue88.67M106.75M81.8M95.06M92.49M
Gross Profit125.39M153.52M129.86M91.3M23.87M
Gross Margin58.6%59.0%61.4%49.0%20.5%
Research & Development11.37M13.42M11.9M12.79M18.01M
Selling, General & Admin58.19M63.56M66.63M63.84M74.92M
Operating Expenses73.01M87.69M84.87M74.86M92.12M
Depreciation & Amortization16.01M18.8M23.91M24.16M25.96M
EBITDA70.12M85.55M72.1M42.6M(42.52M)
EBITDA Margin32.8%32.9%34.1%22.9%-36.5%
Operating Income52.38M65.83M44.99M16.44M(68.25M)
Operating Margin24.5%25.3%21.3%8.8%-58.7%
Interest Income112K114K312K231K96K
Interest Expense1.05M2.84M4.42M4.04M3.4M
Other Income / Expenses683K(1.92M)(1.22M)(2.05M)(3.62M)
Income Before Tax53.07M63.91M43.76M14.39M(71.87M)
Pre-Tax Margin24.8%24.6%20.7%7.7%-61.8%
Income Tax Expense6.6M8.17M6.25M924K11.1M
Net Income38.96M46.74M31.46M11.31M(69.78M)
Net Margin18.2%18.0%14.9%6.1%-60.0%
EPS (Basic)0.851.020.690.24(1.40)
EPS (Diluted)0.830.990.670.24(1.40)
Weighted Avg Shares45.67M45.67M45.67M47.17M47.35M
Weighted Avg Shares (Diluted)47.17M47.17M47.17M47.17M47.35M

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.